Fusion Pharmaceuticals Inc.

This study tests a new drug, FPI-2265, which delivers targeted radiation to prostate cancer cells. It is for adults with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has worsened after prior treatment with another radiation therapy. The goal is to find t…

This study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the treatment can shrink tumors and lower PSA levels while monitoring side effects. Participants must have tri…

This phase II trial tests a new drug called FPI-2265 for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful radioactive particle directly to cancer cells. The main goal is to see if it can lower PSA levels by a…